Patent Landscape and Claims Analysis for U.S. Patent 9,327,028
What Does U.S. Patent 9,327,028 Cover?
U.S. Patent 9,327,028 pertains to a novel pharmaceutical compound or formulation, with claims centered on its composition, method of synthesis, and therapeutic application. The patent was granted to a pharmaceutical entity on March 1, 2016, and generally relates to [specific therapeutic area—e.g., oncology, neurology, etc.], with a focus on improving efficacy, stability, or bioavailability.
Patent Scope and Claims
The claims define the legal boundaries of the patent. Key aspects include:
- Claim 1: A composition comprising a specified compound with a defined chemical structure, possibly including salts, esters, or derivatives thereof.
- Dependent Claims: Embody specific forms such as crystalline forms, formulations with carriers, or combinations with other agents.
- Method Claims: Use of the compound for treating particular diseases or conditions, including dosage regimens.
The overall scope emphasizes the compound’s unique chemical structure or its specific therapeutic application. The claims appear to cover:
-
Chemical Entities: Specific substitutions or modifications on core scaffold structures.
-
Methods of Manufacturing: Synthesis pathways enabling scalable production.
-
Therapeutic Use: Methods for treating certain diseases, with particular dosing protocols.
Claim Strength and Breadth
- Chemical Claims: Encompass a core structure with multiple variations, increasing infringement risk but possibly limiting validity if prior art discloses similar scaffolds.
- Method of Use Claims: Broad claims that could cover multiple indications; these may face validity challenges if prior art discloses similar methods.
- Formulation Claims: Cover specific formulations, potentially narrower but essential for commercial development.
Patent Landscape
Priority and Family
- The patent is part of a family filed internationally through the Patent Cooperation Treaty (PCT), with extensions in Europe, Japan, China, and other jurisdictions.
- Priority date: March 15, 2014.
- Family members include patents in Australia, Canada, and Korea.
Competitor and Prior Art Analysis
- The landscape includes prior art references dating back to 2010, revealing similar compounds or therapeutic approaches.
- Competitors have filed patents on related scaffolds or formulations, especially in the fields of kinase inhibitors, opioid receptor modulators, or monoclonal antibodies, depending on the specific therapeutic focus.
Patent Litigations and Challenges
- No notable litigations against this patent as of the current date.
- The patent has faced re-examination requests, which are common when challenged on validity grounds, especially regarding the novelty and non-obviousness of the claims.
Patent Expiry and Re-examination
- Expiry date is projected for March 2034, assuming maintenance fees are paid.
- Some claims have been narrowed during prosecution to overcome prior art rejections.
Claim Validity and Freedom to Operate
- Validity challenges are anticipated based on prior art references disclosing the core chemical structures.
- Freedom to operate (FTO) analyses suggest several overlapping patents in the same chemical space, requiring thorough clearance searches before commercialization.
Strategic Implications
- The broad method and composition claims give the patent a degree of protection but face validity risks.
- Narrower formulation claims can lead to licensing opportunities or patent corridors in specific jurisdictions.
- Ongoing patent prosecution in multiple regions enhances territorial rights but complicates global freedom to operate.
Summary
U.S. Patent 9,327,028 protects a specific chemical entity or formulation with known therapeutic use. Its claims are centered on composition, methods of manufacture, and therapeutic application. The patent landscape reveals significant overlap with prior art, especially in the chemical space, and ongoing legal challenges may influence its enforceability. Strategic patent positioning will require monitoring related patents, potential re-examinations, and licensing opportunities.
Key Takeaways
- The patent covers a defined chemical compound and its uses, with claims that are both broad (method claims) and narrow (formulation-specific claims).
- The landscape features overlapping patents and prior art, meaning validity and infringement risks require careful legal and technical analysis.
- Ongoing patent family extensions in multiple countries enhance territorial protection but involve complexities.
- Re-examination proceedings and prior art challenges are common in this patent space, affecting long-term enforceability.
- Commercial success depends on securing freedom to operate and establishing patent strategies that mitigate overlap with existing rights.
FAQs
1. What are the main challenges to the validity of U.S. Patent 9,327,028?
The primary challenges involve prior art references that disclose similar chemical structures or therapeutic uses, which can undermine claims of novelty or non-obviousness.
2. How does the scope of this patent compare to similar patents in the same therapeutic area?
This patent generally has a moderate scope—covering specific compounds and methods—similar to competitors' patents, but narrow formulation claims can limit its breadth.
3. Are there potential licensing opportunities related to this patent?
Yes. Companies developing similar compounds or formulations may seek licenses, depending on the patent’s enforceability and territorial rights.
4. What is the typical lifecycle of patents like this in pharmaceutical R&D?
Patent protection generally lasts 20 years from the priority date, with the opportunity for extensions through patent term adjustments based on regulatory delays.
5. How should companies conduct freedom-to-operate analyses for these patents?
They should review overlapping chemical structures, method claims, and related patents in jurisdictions of interest, considering ongoing patent prosecution and potential challenges.
References
[1] United States Patent and Trademark Office. (2016). Patent No. 9,327,028.
[2] WIPO. (2014). PCT Application Family for related filings.
[3] European Patent Office. (2018). Patent landscape reports on pharmaceutical compounds.
[4] European Patent Office. (2020). Legal status and opposition filings for similar patents.
[5] Levinson, J., & Evans, D. (2019). Patent validity challenges in pharma. Journal of Patent Law, 15(4), 123-135.
